Faron Pharmaceuticals: Potential expansion into autoinflammatory diseases - Redeye

Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to expand its targeted indications to autoinflammatory diseases. We are excited by the wide applicability of Clever-1 targeting treatments and encouraged that the company is exploring its full potential.

Länk till analysen i sin helhet: https://www.redeye.se/research/1054914/faron-pharmaceuticals-potential-expansion-into-autoinflammatory-diseases?utm_source=finwire&utm_medium=RSS